PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
Phase 3
Completed
- Conditions
- Overactive Bladder
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00138723
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 93
- Registration Number
- NCT00137436
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes
Phase 3
Terminated
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Subcutaneous Insulin
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2010-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 582
- Registration Number
- NCT00137046
- Locations
- 🇲🇽
Pfizer Investigational Site, Monterrey, Nuevo Leon, Mexico
Zithromax EV in Community-Acquired Pneumonia (CAP)
Phase 4
Completed
- Conditions
- Pneumonia
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT00137007
Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy
Phase 1
Completed
- Conditions
- Fungal Infection
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00136968
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Renal Cell Metastasis
- Interventions
- Drug: SU011248 (sunitinib)
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107
- Registration Number
- NCT00137423
- Locations
- 🇨🇭
Pfizer Investigational Site, St. Gallen, Switzerland
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00137449
- Locations
- 🇮🇹
Pfizer Investigational Site, Milano, Italy
Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee
Phase 3
Completed
- Conditions
- Osteoarthritis,Knee
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2008-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00137410
- Locations
- 🇮🇹
Pfizer Investigational Site, Venezia, Italy
Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
Phase 3
Completed
- Conditions
- Hyperlipidemia
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2007-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 900
- Registration Number
- NCT00137462
- Locations
- 🇨🇦
Pfizer Investigational Site, St. Georges de Beauce, Quebec, Canada
Irinotecan Study For Cervical Cancer
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00136955
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath